Safety, tolerability, and efficacy of adjunctive lacosamide in pediatric patients with epilepsy syndromes associated with generalized seizures: Phase 2, open‐label exploratory trial
Epilepsia · 2023
DOI: 10.1111/epi.17741 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Epilepsia, 2023. Verfasst von Stéphane Auvin und 5 weiteren Autor:innen. Beteiligte Einrichtung: Université Paris-Cité, INSERM NeuroDiderot, Paris, France. Hauptthemen laut MEDLINE: Epilepsy, Generalized, Epileptic Syndromes. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: UCB Pharma.
Abstract (Originalsprache)
Objective
To evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of lacosamide (LCM) (up to 12 mg/kg/day or 600 mg/day) as adjunctive therapy in pediatric patients with epilepsy syndromes associated with generalized seizures.
Methods
Phase 2, multicenter, open‐label exploratory trial (SP0966; NCT01969851; 2012‐001446‐18) of oral LCM for epilepsy syndromes associated with generalized seizures in pediatric patients ≥1 month to
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Université Paris-Cité, INSERM NeuroDiderot, Paris, France.
- Pediatric Neurology Department, APHP, Robert Debré University Hospital, ERN EpiCARE member, Paris, France.
- Institut Universitaire de France (IUF), Paris, France.
- Paediatric Clinical Epileptology and Neurophysiology Department, ERN EpiCARE member, University Hospitals of Lyon (HCL), Lyon, France.
- Epilepsy Research Unit, San Juan de Dios Children's Hospital, ERN EpiCARE member, Barcelona, Spain.
- UCB Pharma, Morrisville, North Carolina, USA.
ORCID-Profile: Stéphane Auvin, Alexis Arzimanoglou, Cynthia Beller, Ali Bozorg
Förderung
- UCB Pharma
Zitieren
APA
Auvin, S., Arzimanoglou, A., Beller, C., Floricel, F., Daniels, T., & Bozorg, A. (2023). Safety, tolerability, and efficacy of adjunctive lacosamide in pediatric patients with epilepsy syndromes associated with generalized seizures: Phase 2, open‐label exploratory trial. Epilepsia. https://doi.org/10.1111/epi.17741
Vancouver
Auvin S, Arzimanoglou A, Beller C, Floricel F, Daniels T, Bozorg A. Safety, tolerability, and efficacy of adjunctive lacosamide in pediatric patients with epilepsy syndromes associated with generalized seizures: Phase 2, open‐label exploratory trial. Epilepsia. 2023. doi:10.1111/epi.17741
BibTeX
@article{Auvin2023,
author = {Auvin, Stéphane and Arzimanoglou, Alexis and Beller, Cynthia and Floricel, Florin and Daniels, Tony and Bozorg, Ali},
title = {Safety, tolerability, and efficacy of adjunctive lacosamide in pediatric patients with epilepsy syndromes associated with generalized seizures: Phase 2, open‐label exploratory trial},
journal = {Epilepsia},
year = {2023},
doi = {10.1111/epi.17741}
}
EUVIMED